Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2342 results

Denmark’s Forward Pharma plans IPO

02-10-2014

Denmark-based Forward Pharma A/S today announced it has commenced an underwritten initial public offering…

BiotechnologyFinancialForward PharmaImmunologicals

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyMenariniOncologyOxford BioTherapeuticsResearch

WuXi PharmaTech acquires XenoBiotic Labs

01-10-2014

Chinese pharma, biotech and devices firm WuXi PharmaTech says it has acquired XenoBiotic Laboratories,…

BiotechnologyMergers & AcquisitionsWuXi PharmaTech

Eurofins Genomics expands business into Italy

Eurofins Genomics expands business into Italy

01-10-2014

Eurofins Genomics, the genomics division of Eurofins Scientific Group, has expanded its business into…

BiotechnologyEurofins GenomicsGeneticsItalyMarkets & Marketing

ESMO 2014: Merck's Keytruda and B-MS' Opdivo

ESMO 2014: Merck's Keytruda and B-MS' Opdivo

30-09-2014

Early results from pharma giant Merck & Co on the use of its Keytruda (pembrolizumab) in patients with…

BiotechnologyBristol-Myers SquibbKeytrudaMerck & CoMerck Research LaboratoriesOncologyOpdivoResearchSpain

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

30-09-2014

Avacta Life Sciences, a division of Avacta Group is investing £10 million ($16.2 million) in the launch…

AvactaBiotechnologyResearchUK

NeoGenomics appoints Robert Shovlin as chief operating officer

NeoGenomics appoints Robert Shovlin as chief operating officer

30-09-2014

Cancer-focused genetic testing service provider NeoGenomics has appointed Robert Shovlin as chief operating…

BiotechnologyBoardroomNeoGenomicsOncologyUSA

Biosimilars set to revolutionize global drug development industry

30-09-2014

Intellectual Property and Science business of Thomson Reuters today announced the release of Biosimilars:…

BiosimilarsBiotechnologyGlobalMarkets & MarketingResearch

Karolinska Development appoints Klaus Wilgenbus as interim chief executive

Karolinska Development appoints Klaus Wilgenbus as interim chief executive

30-09-2014

Swedish drug developer Karolinska Development has appointed current board member Klaus Wilgenbus as chief…

BiotechnologyBoardroomKarolinska DevelopmentKlaus WilgenbusSweden

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

29-09-2014

Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi…

Ambit BiosciencesBiotechnologyDaiichi SankyoJapanMergers & AcquisitionsOncologyquizartinib

Servier and Pharmacyclics end collaboration on abexinostat pan-HDAC inhibitor compounds

Servier and Pharmacyclics end collaboration on abexinostat pan-HDAC inhibitor compounds

26-09-2014

French privately-held drugmaker Servier is to end its collaboration with Pharmacyclics in the development…

abexinostatBiotechnologyFranceOncologyPharmacyclicsResearchServier

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

25-09-2014

Switzerland-based Celgene International, a wholly-owned subsidiary of US biotech major Celgene, say that…

AbraxaneBiotechnologyCelgene Corp.OncologyRegulationSwitzerland

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

25-09-2014

French pharma major Sanofi subsidiary Genzyme has entered into a research collaboration with the USA’s…

BiotechnologyFranceGenzymeOphthalmicsRare diseasesSanofi

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

24-09-2014

Baxter International and oncology specialist Merrimack have launched a collaboration to develop and commercialize…

Baxter InternationalBiotechnologyLicensingMerrimackMM-398OncologyUSA

Acorda Therapeutics to acquire Civitas for $525 million

24-09-2014

US biotech firm Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a…

Acorda TherapeuticsBiotechnologyCivitas TherapeuticsCVT-301Mergers & AcquisitionsNeurological

Gilead files for Japanese approval of ledipasvir/sofosbuvir for hepatitis C

24-09-2014

Gilead Sciences has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationsofosbuvir

Gilead's TAF-based HIV regimen meets 48-week primary objective

Gilead's TAF-based HIV regimen meets 48-week primary objective

24-09-2014

Gilead Sciences says that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational…

Anti-viralsBiotechnologyGilead SciencesResearchtenofovir alafenamideUSA

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

24-09-2014

The UK’s drug watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgene Corp.OncologyPricingRegulationRevlimidUK

FDA fast track designation for AstraZeneca’s MEDI3902

FDA fast track designation for AstraZeneca’s MEDI3902

24-09-2014

Anglo-Swedish pharma major AstraZeneca’s global biologics R&D arm, MedImmune has received fast track…

Antibiotics and Infectious diseasesAstraZenecaBiotechnologyMEDI3902MedImmuneRegulationUSA

Celgene’s psoriasis drug Otezla gains FDA approval

Celgene’s psoriasis drug Otezla gains FDA approval

24-09-2014

The US Food and Drug Administration has approved biotech major Celgene’s Otezla (apremilast), an oral,…

BiotechnologyCelgene Corp.DermatologicalsOtezlaRegulationUSA

Servier and CTI Biopharma collaborate on Pixuvri

23-09-2014

Leading French independent drugmaker Servier and US biotech firm CTI BioPharma have entered into an exclusive…

BiotechnologyCTI BioPharmaLicensingOncologyPixuvriServier

1 to 25 of 2342 results

Back to top